Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico

OBJECTIVES. This 6-month follow-up analysis sought to assess whether the early reduction of mortality obtained with a 6-week treatment course of lisinopril or glyceryl trinitrate, or both, in unselected patients with acute myocardial infarction outlasts therapy and is still present after 6 months. The primary outcome of the 6-month follow-up was the combined end point of mortality and severe left ventricular dysfunction. BACKGROUND. The assumption was that the early benefit on remodeling processes may be maintained over a longer period of time, even in the absence of treatment. METHODS. A total of 19,394 patients with acute myocardial infarction were randomized within 24 h of onset of symptoms to a 6-week treatment course of oral lisinopril or open control and, according to a 2 x 2 factorial design, to glyceryl trinitrate or open control. Randomized treatments were stopped after 6 weeks in the absence of specific indications, and the patients were followed up for 6 months. RESULTS. At 6 months, among patients randomized to lisinopril, 18.1% died or developed severe ventricular dysfunction versus 19.3% of those randomized to no lisinopril (2p = 0.03). No difference was found between patients with and without glyceryl trinitrate therapy (18.4% vs. 18.9%, 2p = 0.39). CONCLUSIONS. Although the systematic administration of glyceryl trinitrate started early and continued for 6 weeks after acute myocardial infarction does not yield evidence of benefit, early treatment with lisinopril appears to improve prognosis. This effect seems to carry over the first 6 months from randomization, even after treatment withdrawal.

This article has been cited by other articles:

				W. J. Kostis, L. Thijs, T. Richart, J. B. Kostis, and J. A. Staessen Persistence of Mortality Reduction After the End of Randomized Therapy in Clinical Trials of Blood Pressure-Lowering Medications Hypertension, December 1, 2010; 56(6): 1060 - 1068. [Abstract] [Full Text] [PDF]

				K. P. Alexander, L. K. Newby, P. W. Armstrong, C. P. Cannon, W. B. Gibler, M. W. Rich, F. Van de Werf, H. D. White, W. D. Weaver, M. D. Naylor, et al. Acute Coronary Care in the Elderly, Part II: ST-Segment-Elevation Myocardial Infarction: A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology: In Collaboration With the Society of Geriatric Cardiology Circulation, May 15, 2007; 115(19): 2570 - 2589. [Abstract] [Full Text] [PDF]

				G. C. Sutton, J. E. Otterstad, B.-A. Kirwan, Z. Voko, S. de Brouwer, J. Lubsen, P. A. Poole-Wilson, and ACTION (A Coronary disease Trial Investigating Out The development of heart failure in patients with stable angina pectoris Eur J Heart Fail, March 1, 2007; 9(3): 234 - 242. [Abstract] [Full Text] [PDF]

				A. G. Herman and S. Moncada Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis Eur. Heart J., October 1, 2005; 26(19): 1945 - 1955. [Abstract] [Full Text] [PDF]

				T. J. Gluckman, B. Baranowski, M. D. Ashen, C. A. Henrikson, M. McAllister, J. B. Braunstein, and R. S. Blumenthal A Practical and Evidence-Based Approach to Cardiovascular Disease Risk Reduction Arch Intern Med, July 26, 2004; 164(14): 1490 - 1500. [Abstract] [Full Text] [PDF]

				L. Tavazzi and A. Volpi Remarks About Postinfarction Prognosis in Light of the Experience With the Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto Miocardico (GISSI) Trials Circulation, March 4, 1997; 95(5): 1341 - 1345. [Full Text]

				Early treatment with lisinopril for 6 weeks reduced mortality at 6 months in acute MI Evid. Based Med., August 1, 1996; 1(5): 139 - 139. [PDF]

				Remodeling After MI: How Long to Treat? Journal Watch Cardiology, May 1, 1996; 1996(501): 11 - 11. [Full Text]